<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097470</url>
  </required_header>
  <id_info>
    <org_study_id>HOVON 155 AML</org_study_id>
    <secondary_id>2018-000047-31</secondary_id>
    <secondary_id>2018-674</secondary_id>
    <secondary_id>NL64632.042.18</secondary_id>
    <nct_id>NCT04097470</nct_id>
  </id_info>
  <brief_title>Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients</brief_title>
  <acronym>HO155</acronym>
  <official_title>A Randomized Phase II Multicenter Study to Assess the Tolerability and Efficacy of the Addition of Midostaurin to 10-day Decitabine Treatment in Unfit Adult Acute Myeloid Leukemia and High Risk Myelodysplasia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stichting Hemato-Oncologie voor Volwassenen Nederland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stichting Hemato-Oncologie voor Volwassenen Nederland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate how safe and effective the addition of the new&#xD;
      medicine midostaurin to decitabine is for the treatment of unfit acute myeloid leukemia (AML)&#xD;
      and high-risk myelodysplasia (MDS) patients. Patients who are ineligible for intensive&#xD;
      chemotherapy because of accompanying diseases may opt for gentler treatment. This does not&#xD;
      produce a cure but serves to allow the quality of life to be acceptable for as long as&#xD;
      possible. Decitabine is an example of a gentler treatment. It is effective against leukemia&#xD;
      and has fewer side effects than intensive chemotherapy. Given in courses of 5 successive&#xD;
      days, decitabine is registered for the treatment of AML. There is scientific research to&#xD;
      suggest that decitabine is more effective and generally well tolerated when given in courses&#xD;
      of 10 successive days. Therefore, treatment with 10-day courses of decitabine is the standard&#xD;
      treatment in this scientific research. The aim is to investigate whether this standard&#xD;
      treatment can be improved by adding a new product, midostaurin. Midostaurin is a medicine&#xD;
      that is directed against a specific protein on leukaemia cells (FLT3).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial aims to develop effective treatments for unfit (i.e. Hematopoietic cell&#xD;
      transplantation co-morbidity index (HCT-CI) ≥ 3) in adult (≥ 18 yrs) AML patients, for whom&#xD;
      current treatment strategies are highly unsatisfactory. Therefore new treatment modalities&#xD;
      are introduced and evaluated in multiple parallel randomized phase II studies that will be&#xD;
      conducted within the frame of a master protocol. The scheme of this new design consists of&#xD;
      one arm with one of the currently considered best available treatments for unfit AML patients&#xD;
      (i.e. 10-day decitabine). After a maximum of 3 10-day courses, or less in case of good&#xD;
      response, treatment will be continued with 5-day decitabine courses. This treatment will be&#xD;
      compared to investigational treatments in combination with decitabine.&#xD;
&#xD;
      The competitor of the 10-day decitabine schedule will be 10-day decitabine combined&#xD;
      (sequential) with the tyrosine kinase inhibitor midostaurin (independent of the presence of&#xD;
      FLT3 mutations). The rationale for midostaurin is: 1) single agent midostaurin has shown&#xD;
      efficacy in both FLT3 wild type and mutant AML; 2) it has shown efficacy in a phase III&#xD;
      randomized controlled trial when combined with intensive chemotherapy in FLT3-mutated AML&#xD;
      (RATIFY study); 3) midostaurin has been successfully combined with hypomethylating agents&#xD;
      (azacitidine and decitabine) and improved the response compared with historical response&#xD;
      rates of these drugs, suggesting at least additive affects of midostaurin with&#xD;
      hypomethylating agents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2019</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Complete Remission (CR) / CR with incomplete blood count (CRi) rate</measure>
    <time_frame>4-5 months</time_frame>
    <description>Cumulative CR/CRi rate during 3 cycles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of midostaurin determined by the type, frequency, severity and relationship of adverse events to study treatment</measure>
    <time_frame>5 years</time_frame>
    <description>Safety and tolerability of midostaurin added to 10-day decitabine treatment for AML (type, frequency, severity and relationship of adverse events to study treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy profile</measure>
    <time_frame>4-9 months</time_frame>
    <description>The response rate after first three cycles together with the best response during three cycles and after 9 months will determinine the efficacy profile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>5 years</time_frame>
    <description>The time from registration to induction failure, death or relapse whichever occurs first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>The time from the date of randomization to the date of death, whatever the cause. Patients still alive at the date last contact will be censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay duration</measure>
    <time_frame>4-5 months</time_frame>
    <description>Days of staying in hospital during 3 cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion need</measure>
    <time_frame>4-5 months</time_frame>
    <description>Number of participants with transfusion needs during 3 cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of MRD</measure>
    <time_frame>9 months and at relapse</time_frame>
    <description>Assessment of the prognostic value of Minimal Residual Disease (MRD) by flowcytometry or PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of gene mutations</measure>
    <time_frame>5 years</time_frame>
    <description>Assessment of the predictive value of gene mutations by exploratory analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of baseline physical conditions as measured by the short physical performance battery</measure>
    <time_frame>5 years</time_frame>
    <description>Assessment of the prognostic value of baseline physical and functional conditions using a comprehensive geriatric assessment tool, short physical performance battery (SPPB), on treatment outcome. Total scores (range 0 to 12) will be used to determine physical performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of baseline functional conditions as measured by the activities of daily living</measure>
    <time_frame>5 years</time_frame>
    <description>Assessment of the prognostic value of baseline functional conditions using a comprehensive geriatric assessment tool, activities of daily living (ADL), on treatment outcome. Total points (range 0 to 6) will be used to determine functional condition.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>AML/MDS</condition>
  <arm_group>
    <arm_group_label>Arm A: Decitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cycles 1-3: Decitabine 10-day; depending on day +28 bone marrow (BM) blasts after the previous cycle, next cycle consists of either 5-day (BM blasts &lt; 5%) or 10-day (BM blasts ≥5%) decitabine. Cycles 4 and beyond: 5-day decitabine (in cycles of 4-8 weeks); continuation of these cycles until progression.&#xD;
Dosage for Decitabine 20 mg/m2 i.v.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Decitabine and Midostaurin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1:Decitabine; 10-day schedule (start day +1) + midostaurin (start day +11). Midostaurin is given until 2 days before start next cycle of decitabine. Cycles 2-3: Decitabine 5 or 10-day schedule; depending on day +28 bone marrow blasts of the previous cycle, next cycle consist of either 5-day (BM blasts &lt; 5%) or 10-day (BM blasts ≥5%) decitabine + midostaurin (daily, starting the day after the last dose of decitabine (i.e. day +6 or +11). Midostaurin is given until 2 days before start next cycle. Cycles 4 and beyond: 5-day decitabine (in cycles of 4-8 weeks) followed by midostaurin starting at day +6 until two days before start of next cycle of decitabine; continuation of these cycles until progression. Midostaurin is given until 2 days before start next cycle of decitabine.&#xD;
Dosage for Decitabine 20 mg/m2 i.v.&#xD;
Dosage for Midostaurin 50 mg b.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Decitabine dosage 20mg/m2 i.v.</description>
    <arm_group_label>Arm A: Decitabine</arm_group_label>
    <arm_group_label>Arm B: Decitabine and Midostaurin</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midostaurin</intervention_name>
    <description>Midostaurin 50 mg b.i.d.</description>
    <arm_group_label>Arm B: Decitabine and Midostaurin</arm_group_label>
    <other_name>Rydapt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with:&#xD;
&#xD;
               -  a diagnosis of AML and related precursor neoplasms according to WHO 2016&#xD;
                  classification (excluding acute promyelocytic leukemia) including secondary AML&#xD;
                  (after an antecedent hematological disease (e.g. MDS) and therapy-related AML, or&#xD;
&#xD;
               -  a diagnosis of myelodysplastic syndrome with excess of blasts (MDS) and&#xD;
                  International Prognostic Score System (IPSS) &gt; 4.5&#xD;
&#xD;
          -  Patients 18 years and older.&#xD;
&#xD;
          -  Patients NOT eligible for standard chemotherapy, defined as hematopoietic cell&#xD;
             transplantation comorbidity index (HCT-CI) ≥ 3.&#xD;
&#xD;
        or Patients NOT eligible for standard chemotherapy for other reasons (wish of patient).&#xD;
&#xD;
          -  White blood cell (WBC) ≤ 30 x109/L (prior hydroxyurea allowed for a maximum of 5 days,&#xD;
             stop 2 days before start decitabine treatment)&#xD;
&#xD;
          -  Adequate renal and hepatic functions unless clearly disease related as indicated by&#xD;
             the following laboratory values:&#xD;
&#xD;
               -  Serum creatinine ≤ 221.7 µmol/L (≤ 2.5 mg/dL ), unless considered AML-related&#xD;
&#xD;
               -  Serum bilirubin ≤ 2.5 x upper limit of normal (ULN), unless considered&#xD;
                  AML-related or due to Gilbert's syndrome&#xD;
&#xD;
               -  Alanine transaminase (ALT) ≤ 2.5 x ULN, unless considered AML-related&#xD;
&#xD;
          -  WHO performance status 0, 1 or 2.&#xD;
&#xD;
          -  Patient is willing and able to use adequate contraception during and until 5 months&#xD;
             after the last protocol treatment.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Patient is capable of giving informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukemia.&#xD;
&#xD;
          -  Acute leukemia's of ambiguous lineage according to WHO 2016&#xD;
&#xD;
          -  Patient has symptomatic central nervous system (CNS) leukemia (NO routinely lumbar&#xD;
             puncture required to investigate CNS involvement)&#xD;
&#xD;
          -  Blast crisis of chronic myeloid leukemia.&#xD;
&#xD;
          -  Diagnosis of any previous or concomitant malignancy is an exclusion criterion:&#xD;
&#xD;
          -  except when the patient completed successfully treatment (chemotherapy and/or surgery&#xD;
             and/or radiotherapy) with curative intent for this malignancy at least 6 months prior&#xD;
             to randomization. OR&#xD;
&#xD;
          -  except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the&#xD;
             cervix&#xD;
&#xD;
          -  Patients previously treated for AML (any antileukemic therapy including&#xD;
             investigational agents), a short treatment period ( ≤ 5 days) with Hydroxyurea is&#xD;
             allowed&#xD;
&#xD;
          -  Current concomitant chemotherapy, radiation therapy, or immunotherapy; other than&#xD;
             hydroxyurea&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes,&#xD;
             infection, hypertension, pulmonary disease etc.)&#xD;
&#xD;
          -  Cardiac dysfunction as defined by:&#xD;
&#xD;
               -  Myocardial infarction within the last 3 months of study entry, or&#xD;
&#xD;
               -  Reduced left ventricular function with an ejection fraction &lt; 40% as measured by&#xD;
                  MUGA scan or echocardiogram or&#xD;
&#xD;
               -  Unstable angina or&#xD;
&#xD;
               -  New York Heart Association grade IV congestive heart failure or&#xD;
&#xD;
               -  Unstable cardiac arrhythmias.&#xD;
&#xD;
          -  History of stroke or intracranial hemorrhage within 6 months prior to randomization.&#xD;
&#xD;
          -  Patient has a history of human immunodeficiency virus or active infection with&#xD;
             Hepatitis C or B.&#xD;
&#xD;
          -  Patients known to be pregnant&#xD;
&#xD;
          -  Patients with a history of non-compliance to medical regimens or who are considered&#xD;
             unreliable with respect to compliance.&#xD;
&#xD;
          -  Patients with any serious concomitant medical condition which could, in the opinion of&#xD;
             the investigator, compromise participation in the study.&#xD;
&#xD;
          -  Patients who have senile dementia, mental impairment or any other psychiatric disorder&#xD;
             that prohibits the patient from understanding and giving informed consent.&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerwin Huls, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG / HOVON</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerwin Huls, Prof.</last_name>
    <phone>+31503612354</phone>
    <email>g.huls@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>E. Ammatuna, Dr.</last_name>
    <phone>+31503612354</phone>
    <email>e.ammatuna@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UH Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fischer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cuijpers</last_name>
    </contact>
    <investigator>
      <last_name>Cuijpers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Groep</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Posthuma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Herbers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>van Lammeren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slingeland Ziekenhuis</name>
      <address>
        <city>Doetinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Aboosy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Westerweel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Velders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Cruijsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima MC</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Huls</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Söhne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>de Jonge-Peeters</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMCU</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Van Rhenen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KSA</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bargetzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USB</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Heim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IOSI</name>
      <address>
        <city>Bellinzona</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stussi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insel</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pabst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HFR</name>
      <address>
        <city>Fribourg</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Betticher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCUGE</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Chalandon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Blum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KSL</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gregor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KSSG</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fehr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USZ</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Manz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.hovon.nl</url>
    <description>HOVON website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Midostaurin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

